• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Korro Bio Inc.

    4/29/25 6:06:51 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    DEFA14A 1 korro_defa14a_2025.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

     

    Check the appropriate box:

     

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

     

    Korro Bio, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

    Payment of Filing Fee (Check all boxes that apply):

     

     

    ☒

    No fee required

     

     

    ☐

    Fee paid previously with preliminary materials

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     


     

    img161143922_0.jpg

     

    korro bio P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Korro Bio, Inc. Annual Meeting of Stockholders Wednesday, June 11, 2025 11:00 AM, Eastern Time Annual meeting to be held via the Internet - please visit www.proxydocs.com/KRRO for more details. You must register to attend the meeting online and/or participate by 5:00 PM ET on June 10, 2025 at www.proxydocs.com/KRRO. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/KRRO To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 30, 2025. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 11, 2025 for Stockholders of Record as of April 15, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/KRRO Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

     


     

    img161143922_1.jpg

     

    korro bio Korro Bio, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR THE NOMINEES IN PROPOSAL 1, FOR A FREQUENCY OF ONE YEAR IN PROPOSAL 3 AND FOR PROPOSALS 2 AND 4 PROPOSAL 1. Election of three Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders; 1.01 Ram Aiyar 1.02 Jean-Francois Formela 1.03 Katharine Knobil 2. Non-Binding Advisory Vote to Approve the Compensation of our Named Executive Officers; 3. Non-Binding Advisory Vote on the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of our Named Executive Officers 4. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 5. Transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.

     


     

     


    Get the next $KRRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    1/29/2026$30.00Neutral → Overweight
    Piper Sandler
    1/29/2026$15.00Neutral → Buy
    Chardan Capital Markets
    1/29/2026$20.00Neutral → Buy
    H.C. Wainwright
    1/28/2026$21.00Neutral → Overweight
    Cantor Fitzgerald
    1/28/2026$22.00Perform → Outperform
    Oppenheimer
    11/13/2025$8.00Outperform → Sector Perform
    RBC Capital Mkts
    11/13/2025Overweight → Neutral
    Cantor Fitzgerald
    11/13/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Aiyar Ram was granted 40,000 shares (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    2/3/26 4:17:03 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Vincent Loic A

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    2/3/26 4:14:02 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Senior Vice President, Finance Dolan Oliver

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    2/3/26 4:11:04 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.

    SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    2/5/26 1:28:06 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Korro Bio Inc.

    SCHEDULE 13G - Korro Bio, Inc. (0001703647) (Subject)

    1/30/26 3:25:14 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Korro Bio Inc.

    S-8 - Korro Bio, Inc. (0001703647) (Filer)

    1/27/26 4:05:27 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Korro to Host Virtual Analyst Day on January 27, 2026

    - Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management team, Bruce Scharschmidt, MD, hepatologist and former Chief Medical Officer of Hyperion Therapeutics, and Michelle Dinon, parent of a child impacted by a urea cycle disorder (UCD). Korro

    1/20/26 8:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro's website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days. About Korro Korro is a biop

    1/8/26 8:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

    CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- —KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients  —KRRO-110 did not reach projected levels of functional protein following a single administration    —Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026  —Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia  —Reports third quarter 2025 financial results; ended third quarter 2025 with $102.5 million in cash, cash equivalents and marketable securities; extending cash runway into second half of 2027 by impleme

    11/12/25 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Korro Bio upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Korro Bio from Neutral to Overweight and set a new price target of $30.00

    1/29/26 6:58:39 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Korro Bio from Neutral to Buy and set a new price target of $20.00

    1/29/26 6:58:28 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Bio upgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets upgraded Korro Bio from Neutral to Buy and set a new price target of $15.00

    1/29/26 6:58:28 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    4/24/24 5:00:19 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    4/24/24 5:00:26 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    4/24/24 5:00:16 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 7:54:42 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 3:04:22 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 12:21:08 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    View All

    Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    4/1/25 7:30:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

    - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

    11/12/24 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care